Objective: This study aimed to evaluate the quality of enhancement and solid-organ lesion depiction using weight-based intravenous (IV) contrast dosing calculated by injector software versus fixed IV contrast dose in oncologic abdominal computed tomographic (CT) examinations.
T he optimal computed tomographic (CT) scanning of patients requires a tailored approach that takes into account multiple factors inherent to the patient, scanner, contrast media, and clinical scenario. With an increased focus on personalized medicine, precise and highly reproducible scanning is required, beyond what has already been achieved. Particularly in oncology, variations in image quality and contrast phase can limit the detection of disease or subtle interval changes in a tumor. [1] [2] [3] Reducing this variability is becoming increasingly important as earlier predictive and accurate tumor response assessment to treatment is desired.
Contrast injection protocols have been an area of intense research in an effort to improve diagnostic accuracy. [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] Specifically, the timing and degree of organ enhancement play critical roles in oncologic lesion detection. 14 This has historically been optimized by altering the iodine contrast concentration, volume, and injection rate, as well as through the use of a saline chaser. 15 Although optimized contrast injection parameters are critical for robust imaging, further attention must be given to patient-related factors that affect imaging and can be partially mitigated. These include conditions such as congestive heart failure, which alters cardiovascular circulation and thus contrast enhancement, as well as body habitus. [16] [17] [18] [19] [20] [21] Studies have shown that maximum hepatic enhancement is inversely related to body weight. 21, 22 Furthermore, work such as that by Ho et al 11 and Kondo et al 12 has shown other parameters such as lean body weight to better correlate with contrast enhancement compared with total body weight (TBW). Despite longstanding published literature, our experience has been that highly personalized injection protocols are not typically used likely because this would require an operational change that would include calculations or additional software and because the results of a more simplified approach are typically adequate for clinical purposes.
Weight-based contrast injection can provide multiple benefits during imaging. First, larger patients are often underdosed with respect to intravenous (IV) contrast, and thus, weight-based dosing (WBD) can improve contrast enhancement. 23 Second, smaller patients typically receive more contrast than needed, which can potentially increase the risk of contrast-induced neuropathy in at-risk patient populations. [24] [25] [26] [27] [28] Third, WBD can allow for more precise tailoring of the IV contrast load based on clinical necessity such as allowing for more contrast for the presurgical staging of the liver versus less contrast for the clinical evaluation of possible appendicitis. In smaller patients, there are also potential cost savings, especially when lower kilovoltage protocols are used because similar enhancement can be obtained at lower IV contrast doses. [29] [30] [31] [32] [33] The purpose of our study was to evaluate abdominal CT for quality of contrast enhancement, solid-organ lesion depiction, and contrast volume distribution across patient sizes between commercially available injector software that uses weight-based IV contrast injection and our fixed-contrast dose oncologic protocols. We also correlated the calculated contrast volumes from the scanner software with TBW, body mass index (BMI), and body surface area (BSA).
MATERIALS AND METHODS
This Health Insurance Portability and Accountability Actcompliant retrospective cohort study was approved by our quality improvement board (institutional review board exempt), and the need for informed consent was waived.
Patient Population
After instituting the use of weight-based contrast IV volume adjustment on a single scanner, patients were selected (66 men, 68 women; mean age, 59 years; age range, 23-80 years). Power analysis assumed a 0.5 difference in the mean quality scores and an SD of 1; 128 patients would yield 80% power to detect this difference with a 2-sided type I error rate of 5%. The radiology information system at our institution, a tertiary oncologic center, was searched for patients who had undergone contrast-enhanced CT scanning of the abdomen from December 1, 2016, to January 15, 2017, with our single-phase WBD protocol using WBD software and who also had an otherwise equivalent fixed-contrast dose before examination for comparison. This search yielded matched protocol specifications and injection parameters without the need of exclusion criteria.
Age, sex, weight, height, primary cancer type, and BMI were recorded for each patient. Body surface area was calculated using 2 equations, BSA1 ((kg Â cm) 1/2 )/60) 34 and BSA2 (0.1173 Â kg 0.6466 ). BSA1 is the commonly used Mosteller method, which is also used at our institution for the calculation of certain chemotherapeutic dosing regimens. BSA2 is another commonly used calculation elsewhere, which has been reported to be more accurate in obese patients than a third BSA calculation using the Du Bois equation. 35 The number of days between the WBD and fixed-contrast dose examinations was recorded.
Imaging Parameters
All patients underwent CT scanning of the abdomen using an identical imaging protocol performed on a Revolution CT system (GE Healthcare): gantry speed of 0.7 seconds, pitch of 0.5:1, table speed of 40 mm/rotation, beam collimation of 80 mm with detector configuration of 128 Â 0.6 mm, and 120 kVp using tube current modulation.
Standard routine protocols at our institution vary injection parameters based on axial digital field of view (DFOV) selected by the technologist: patients with a prescribed DFOV of 40 and less receive 125 mL of IV contrast injected at 3 mL/s, and those with a DFOV of 42 and greater receive 150 mL of IV contrast injected at 4 mL/s. The type of IV contrast is selected based on an estimated glomerular filtration rate (eGFR) cutoff of 45 mL/ min per 1.73 m 2 . In our study, 129 patients received 350 mg of iodine per milliliter as iohexol (Omnipaque 350; General Electric, Waukesha, WI), and 5 patients received 320 mg of iodine per milliliter as iodixanol (Visipaque 320; General Electric). The WBD studies were matched to fixed-dose examinations for identical IV contrast injection rate and contrast type.
Certegra P3T software (Bayer HealthCare, LLC, Whippany, NJ) was used to prescribe contrast volume based on input values of weight and iodine concentration using a weight factor of 0.6 gI/kg and maximum volume of 150 mL. This was the highest weight factor allowed, which empirically provided the best match to our standard examinations.
Weight-based dosing and fixed-dose examinations were performed with bolus tracking using a 100-Hounsfield unit (HU) trigger value in the abdominal aorta at the level of the celiac artery and a scan delay of 46 seconds to obtain a portovenous phase of scanning followed by a 120-second delay phase of the kidneys and urinary bladder.
Patients were categorized as large and small based on DFOV size into group L (DFOVof ≥42) and group S (DFOVof ≤40), respectively. Group S was further divided by the amount of IV contrast suggested by the injection software. During the initial assessment of this software at our institution, we empirically noted that the enhancement quality was noticeably inferior below an approximate software-suggested level of 110 mL of IV contrast (38.5 g of iodine). Therefore, we subdivided group S into S low and S high for patients receiving less than or more than 38.5 g of IV iodine, respectively.
Qualitative Analysis
Two radiologists (S.G. and N.W.-B., with 5 and 7 years of post-fellowship experience in abdominal imaging) qualitatively assessed the quality of contrast enhancement in each WBD examination and the relevant comparison examination using 2.5-mm reconstructions.
The examinations were reviewed independently for 3 sessions. The WBD examinations were rated for overall contrast enhancement quality against our standard high-quality oncologic comparison examinations using a previously published comparative scale. 36 A score of 4 was to be given if the WBD examination was markedly superior (likely improving diagnosis), 3 for moderately superior (probable influence on diagnosis), 2 for mildly superior (possible influence on diagnosis), 1 for slightly superior (no influence on diagnosis), 0 for no clear difference between examinations, −1 for slightly inferior (no influence on diagnosis), −2 for mildly inferior (possible influence on diagnosis), −3 for moderately inferior (probable influence on diagnosis), and − 4 for markedly inferior (likely impairing diagnosis).
Using the same rating scale, images were also reviewed for focal, noncalcified lesions within the solid organs. The number, type, and organ location were recorded for each lesion, and a single, overall score for lesion depiction was provided for each patient. The first reader for each case marked lesions so that the same lesions were reviewed by both readers; this study did not aim to assess lesion detection accuracy.
There was no time limit for image review.
Quantitative Analysis
Authors not involved in the qualitative interpretation of images (K.B., radiology resident; L.V., abdominal radiology fellow) measured numerous 2-dimensional regions of interest (ROI) on the WBD and comparison examinations: 3 regions within the liver at the level of the portal vein bifurcation, main portal vein (MPV), each hepatic vein, each psoas muscle, suprarenal and infrarenal inferior vena cava suprarenal and infrarenal (IVC), aorta at the celiac artery origin, spleen, and right and left subcutaneous fat. No ROIs were obtained on images with artifacts, and any focal abnormality such as calcification was carefully avoided.
The contrast-to-noise ratio (CNR) relative to psoas muscle was calculated for the liver using the equation (ROI i − ROI m )/SD, where ROI i is the mean HU value for the anatomy of interest, ROI m is the mean HU value of psoas muscles, and SD is the mean image noise based on subcutaneous fat using the average SD in HUs. 37, 38 Liver-to-spleen ratios were calculated for the WBD and comparison examinations on both the portovenous and delayed contrast phases.
A value of "total vascular enhancement" (TVE) was calculated, which represents the summation of HUs in the MPV, average of the 3 hepatic veins, aorta, infrarenal IVC, and suprarenal IVC. Total vascular enhancement was also calculated per gram of injected iodine in each patient (TVE/gI). A difference in HUs of 10 was considered clinically significant because previous studies have shown that reviewers are not consistently able to identify differences in HUs below this level.
39,40

Statistical Analyses
Summaries of reader scores and of HU ROIs were provided in frequencies, mean, SD, and range. Weighted κ statistics (quadratic weights) was used to assess agreement between 2 readers. A linear mixed model was used to estimate and compare mean reader scores based on DFOV status. Patient level was included in the mixed model as a random effect. Hounsfield unit ROIs were analyzed and compared by DFOV using analysis of variance. Comparisons between WBD and fixed-dose scan were performed using the paired t test. Linear regression was used to evaluate the relationship between weight, BMI, BSA1, and BSA2 compared with TVE/gI and contrast volume. All tests were 2-sided, and P values of 0.05 or less were considered statistically significant. Statistical analyses were carried out using SAS version 9.4, and regression lines were plotted using JMP 12 (SAS Institute, Cary, NC).
RESULTS
Patient Characteristics
The 134 patients who met the study criteria were assessed together and between subsets. The entire group's mean BMI was 27.79 ± 7.26 kg/m Table 1 ).
The frequency of primary neoplasms in descending order was as follows: melanoma (n = 23), breast (n = 19), sarcoma (n = 19), colon (n = 15), prostate (n = 9), renal cell carcinoma (n = 7), lung (n = 6), squamous cell (n = 6), endometrial (n = 5), gastric (n = 4), peritoneal (n = 3), pancreas (n = 3), biliary (n = 3), small intestine (n = 2), appendiceal (n = 2), lymphoma (n = 2), testicular (n = 2), and single cases of epithelioid angiomyolipoma, desmoplastic small round cell tumor, ovarian, cervical, and esophageal malignancies.
The mean number of days between WBD and comparison examinations was 113 ± 77 days.
Qualitative Image Analysis
Enhancement (estimated mean -0.05, 95% CI [−0.19 to 0.09], P = 0.46) and lesion depiction (estimated mean −0.01, 95% CI [−0.10 to 0.07], P = 0.79) scores did not differ between CT examinations using weight-based IV contrast versus fixed IV contrast dosing when a minimum of 38.5 g of iodine was used. However, the scores using weight-based IV contrast dosing were lower when the injector software calculated and delivered less than 38.5 g of iodine (estimated mean −0.81, 95% CI [−1.06 to −0.56], p < 0.0001). Enhancement scores and lesion depiction scores of WBD versus fixed dose examinations were significantly lower in the Slow subgroup, whereas Groups L and Shigh subgroups were not significantly different (Table 2) . With a volume threshold difference of 15 mL between IV contrast usage of WBD and comparison examinations, a higher volume was used in 17 WBD cases, a lower volume was used in 32 cases, and The frequencies of reader scores are listed in 
Quantitative Image Analysis
There were no clinically significant differences in the measured HUs for the entire group of patients (each size group combined) comparing WBD with the standard fixed-dose examinations; the liver measured 5 HUs lower in the WBD group, which was statistically significant (P = 0.001). However, when assessing by DFOV subgroups, HUs for the S low group were significantly lower with WBD in the MPV, aorta, liver, and TVE. The S low group also did not demonstrate the improved CNR with WBD that was seen in the L and S high groups. Conversely, the S high group demonstrated higher HUs in the MPV, aorta, and TVE; however, the liver HUs were not significantly different for WBD versus fixed-dose examinations (Table 4) .
When comparing HUs between DFOV groups within just the WBD examinations, HUs were significantly lower in group L than in group S high for MPV, with a mean difference of −22.17 ± 5.67 (95% confidence interval [CI], −33.38 to −10.96; P = 0.0001), and for TVE, with a mean difference of −59.12 ± 22.38 (95% CI, −103.40 to −14.84; P = 0.009); the only other significant difference was lower HUs for the MPV in group S low compared with S high with a mean difference of −25.24 ± 6.79 (95% CI, −38.66 to −11.81; P = 0.0003).
The mean image noise on WBD examinations for groups S low , S high , and L was 9.5 ± 2.5 (range, 4.6-15.4), 9.9 ± 2.3 (range, 5.2-15.6), and 9.8 ± 2.2 (range, 6-15.3), respectively; on the comparison examinations, the respective noise was 10.3 ± 2.5 (range, 5.7-15.8), 10.6 ± 2.6 (range, 4.4-18.2), and 10.6 ± 1.9 (range, 6.6-15.5).
Regression analyses were performed on contrast volume and TVE/gI. Weight, BSA1, and BSA2 correlated well and similarly to one another versus contrast volume and TVE/gI across groups S low , S high , and L; respective R 2 values for the entire group (each size group combined) were 0.78, 0.79, and 0.81 and 0.58, 0.65, and 0.59. Conversely, R 2 values for BMI with contrast volume and TVE/gI were only 0.56 and 0.26, respectively.
DISCUSSION
Our study revealed that, when selecting an appropriate minimum IV iodine contrast dose, the quality of contrast enhancement and solid-organ lesion depiction can be preserved and a better distribution of contrast usage can be obtained when using weightbased injector software. Weight-based IV contrast injection using injector software has not been specifically evaluated in the abdominal literature, although the commercially available software is available to many practices. There was no overall significant contrast-related difference between WBD examinations and our standard fixed-contrast dosing of examinations; however, importantly, a portion of patients in each size group were better optimized to receive an increased or decreased contrast dose through the use of WBD. Qualitative evaluation of overall contrast enhancement and lesion depiction found no significant difference between WBD and fixed-dose examinations in group L or group S high . Quantitatively, the only statistically significant difference between the entire combined groups of WBD versus comparison examinations was in the liver; however, this difference of 5 HU is not considered clinically significant. Previous studies have shown that reviewers are not consistently able to identify differences in HUs of less than 10. 39, 40 When assessing by group level, group S high had statistically and clinically significant improvement in quantitative enhancement in the MPV, aorta, and TVE. Interestingly, when assessing between-group levels, group L was significantly lower than group S high for HUs in the MPV and TVE; this is attributable to the setting of maximum contrast volume at 150 mL. Depending on the intended clinical use, increasing this maximum level could be considered to maintain an even distribution of contrast usage and thus image quality. Improvements in CNR liver noted on WBD examinations for groups L and S high were related to mild differences in noise between examinations.
Our results with a larger sample size, specifically in an oncologic population with lesion evaluation, support those of George et al, 41 which also showed an improved distribution of contrast enhancement and image quality across a spectrum of patient sizes using WBD. George et al also demonstrated the use of TBW to be an acceptable measure for the choice of contrast volume, as did Svensson et al. 42 This finding was reproduced in the current study, which showed that TBW and BSA performed similarly when compared with our vendor-specific injection software that uses a proprietary calculation. Of note, BMI correlated very poorly with these measures and thus would not be well suited to define contrast volume groups in clinical practice.
Our WBD examinations allow for an IV contrast range of 110 to 150 mL when using the injector software. The choice of a 110-mL minimum volume (38.5 g of iodine) was made during implementation when an empiric loss of contrast was noted near this level, although the software suggested a lower volume based on patient weight. One subset, group S low , of smaller patients was identified in our study to assess this empiric observation. In addition, this subset was used to determine whether image quality could be maintained during reduced contrast volume, which could potentially be used such as in the setting of renal impairment. Although contrast-induced acute kidney injury has been shown to be rare in patients with a stable eGFR of 45 mL/min per 1.73 m 2 or greater, contrast risk in patients with a stable eGFR of 30 to FIGURE 1. A-D, Two case examples from different patients, each demonstrating a small benign finding (a lesion that is unchanged between examinations) for comparison between fixed-dose (A and C) and WBD (B and D) examinations when IV contrast load was allowed less than 110 mL (38.5 g of iodine) on the WBD examination. Inferior overall enhancement and lesion depiction were noted qualitatively by readers and upon quantitative measurements for the WBD cases. Readers noticed that a subtle splenic lesion (A, arrow) and the nodular enhancement of a hemangioma (C, arrow) were only barely seen on the WBD examinations.
44 mL/min per 1.73 m 2 is controversial, according to recent conflicting evidence, and those with a stable eGFR of less than 30 mL/min per 1.73 m 2 are still considered to be at increased risk. 43 It remains reasonable to use the least amount of IV contrast as possible and to consider more aggressive reduction of contrast volume in patients with impaired renal function. There was a noticeable reduction in image quality in group S low for which the minimum contrast volume of 110 mL (38.5 g of iodine) was removed, allowing the software a full lower range of volume selection (Fig. 1) . Readers rated overall contrast enhancement and lesion depiction to be inferior in group S low , and HUs were significantly lower for the MPV, aorta, liver, and TVE (Tables 2 and 4 ). This insufficient enhancement in small patients even while using the same gI/kg level has been previously recognized, and the use of lean body weight has been proposed to mitigate this limitation. 44 Unfortunately, this limitation was still apparent with the use of our vendor-specific injector WBD software.
When assessing the choice of fixed-dose versus WBD, image quality and patient safety are most important. However, there are also implications of cost to be considered. With the historical use of a single division of patients into 2 fixed-dose IV contrast volume groups at our institution, we suspected that there would be 3 categories of effect by using WBD: one in which there was no significant difference in contrast volume, a group of slightly above-average patient sizes that would receive less contrast than our standard, and a group of slightly below-average patient sizes that would receive an increased contrast volume relative to our standard. This was confirmed in our study; our group of large patients (group L) received a mean dose of 0.54 gI/kg with WBD versus 0.58 gI/kg on comparison examinations, and our group of smaller patients (group S high ) received a mean dose of 0.60 gI/kg versus 0.57 gI/kg on comparison examinations. Specifically, 32 WBD cases used a lower volume in group L and 17 WBD cases used a higher volume in group S high than did those on the comparison examinations. In our practice, the degree of cost savings would likely be muted by our need to maintain robust oncologic imaging quality, particularly of the liver. A range of 0.489 to 0.75 gI/kg has been reported as the necessary contrast dose for proper hepatic enhancement. Kondo et al 12, 23 demonstrated that 0.6 gI/kg TBW was an important level, above which resultant images were deemed to be good quality in more than 90% of patients. 44 Kondo et al also showed that patients receiving 22 gI/m 2 based on BSA had an even better correlation with enhancement than did the TBW group; the mean values from our study were 23.97 and 23.35 gI/m 2 using BSA1 and BSA2 methods of calculation, respectively. Using the calculation from Heiken et al 22 and our target gI/kg of 0.6, our detailed oncologic evaluations seem to require a mean hepatic enhancement (mean ΔHU) of 57.6 HU. Using data from Davenport et al 45 and comparing to their fixed-dose protocol of 125 mL, there is a projected additional cost of $102,384 for a sample of 6737 patients if a TBW factor of 0.625 gI/kg was used with a 150-mL maximum contrast load. Although products and pricing contrast vary between institutions, we suspect that this projection would apply to our group S and that a cost savings, similar in degree, would apply to our group L.
There were some limitations in our study. First, inherent in studies between 2 time points, the clinical status of the patient may change. In our study, the most commonly expected change would be variation in hepatic steatosis between examinations related to chemotherapeutic regimens. To account for this, we calculated the HU Liver-to-spleen ratio on every examination, and there was no significant change between time points. In addition, a change in cardiovascular status was a potential concern between examinations; we address this in our standard clinical practice, and we addressed this in the study through the detailed use of contrast bolus tracking. Second, our study was retrospective and not intended to directly assess potential clinical impact, which requires further investigation. Furthermore, the type and degree of effects related to WBD software implementation will vary depending on the initial protocols used within each practice.
In conclusion, weight-based contrast dosing using injector software maintained or improved IV contrast enhancement and lesion depiction across patient sizes when using a minimum contrast volume of 110 mL (38.5 g of iodine). Total body weight and BSA correlated well with the software-selected contrast volumes, whereas BMI was a poor predictor of IV contrast volume needed to maintain contrast enhancement across patient sizes. Our study, which used WBD relative to our standard fixed-dosing approach, suggests that patients of above-average size present opportunities for lowering contrast usage, whereas certain patients of belowaverage size may benefit from an increased amount of contrast with WBD.
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